Bristol’s $1.5B Orbital buyout extends ‘in vivo’ cell therapy deal streak

The acquisition of the well-funded startup is the fourth this year involving companies with technologies that can genetically modify immune cells inside the body. 

A regenerative therapy for hair loss attracts a mega-fundraising round

Backed by GV and Arch Venture Partners, Pelage Pharmaceuticals is advancing a first-of-its-kind topical gel designed to activate dormant hair follicle stem cells.

Inside the world of cell therapies

AstraZeneca cuts US drug pricing deal; FDA declares Novo plant out of compliance

AstraZeneca followed the blueprint of a deal Pfizer recently cut with the White House. Elsewhere, Novo is shuttering its cell therapy division and an investor wants Novavax to sell itself.

A gene therapy pioneer reckons with the reality for ultra-rare diseases

Sarepta to seek approval for gene therapy in rare muscular dystrophy

Exposure to any germs could’ve killed her. 11 years later, she’s living a normal life thanks to a gene therapy treatment.